| Rank |
Title |
Year |
PubWeight™‹?› |
|
1
|
Microglia in ischemic brain injury.
|
2010
|
1.36
|
|
2
|
Autophagy in neuroprotection and neurodegeneration: A question of balance.
|
2008
|
1.31
|
|
3
|
Inter-relationships among behavioral markers, genes, brain and treatment in dyslexia and dysgraphia.
|
2010
|
1.26
|
|
4
|
From singing to speaking: facilitating recovery from nonfluent aphasia.
|
2010
|
1.18
|
|
5
|
Evidence for RNA-mediated toxicity in the fragile X-associated tremor/ataxia syndrome.
|
2009
|
1.17
|
|
6
|
Neurobiology of dysregulated motivational systems in drug addiction.
|
2010
|
1.14
|
|
7
|
Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent.
|
2009
|
1.09
|
|
8
|
REST and the RESTless: in stem cells and beyond.
|
2009
|
1.06
|
|
9
|
The role of neuregulin-1 in the response to nerve injury.
|
2011
|
1.03
|
|
10
|
Is abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimer's disease?
|
2009
|
1.02
|
|
11
|
Antidepressant-coincident mania in children and adolescents treated with selective serotonin reuptake inhibitors.
|
2009
|
0.98
|
|
12
|
α-synuclein, LRRK2 and their interplay in Parkinson's disease.
|
2012
|
0.97
|
|
13
|
Sex-specific responses to stroke.
|
2010
|
0.96
|
|
14
|
Developmental hearing loss disrupts synaptic inhibition: implications for auditory processing.
|
2009
|
0.96
|
|
15
|
Opening Pandora's jar: a primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neuron, and central disorders.
|
2012
|
0.95
|
|
16
|
Alzheimer's disease and epilepsy: insight from animal models.
|
2012
|
0.94
|
|
17
|
Astroglia in neurological diseases.
|
2013
|
0.94
|
|
18
|
Development of histone deacetylase inhibitors as therapeutics for neurological disease.
|
2009
|
0.93
|
|
19
|
Clearance of amyloid-β peptides by microglia and macrophages: the issue of what, when and where.
|
2012
|
0.93
|
|
20
|
Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain.
|
2011
|
0.92
|
|
21
|
Essential function, sophisticated regulation and pathological impact of the selective RNA-binding protein QKI in CNS myelin development.
|
2008
|
0.92
|
|
22
|
Diffusion tensor imaging and related techniques in tuberous sclerosis complex: review and future directions.
|
2013
|
0.91
|
|
23
|
Neurodegeneration in spinal muscular atrophy: from disease phenotype and animal models to therapeutic strategies and beyond.
|
2014
|
0.91
|
|
24
|
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.
|
2012
|
0.90
|
|
25
|
What have novel imaging techniques revealed about metabolism in the aging brain?
|
2014
|
0.89
|
|
26
|
Update on the functional biology of Lrrk2.
|
2008
|
0.89
|
|
27
|
The clinical implications of mouse models of enhanced anxiety.
|
2011
|
0.89
|
|
28
|
Modeling neurological diseases using patient-derived induced pluripotent stem cells.
|
2011
|
0.89
|
|
29
|
A new look at glutamate and ischemia: NMDA agonist improves long-term functional outcome in a rat model of stroke.
|
2011
|
0.89
|
|
30
|
Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium.
|
2010
|
0.89
|
|
31
|
Dopamine transporter trafficking: rapid response on demand.
|
2010
|
0.88
|
|
32
|
Experience--a double edged sword for restorative neural plasticity after brain damage.
|
2008
|
0.88
|
|
33
|
Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair.
|
2008
|
0.88
|
|
34
|
Predicting dementia: role of dementia risk indices.
|
2009
|
0.88
|
|
35
|
Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases.
|
2009
|
0.87
|
|
36
|
Neural pathways for language in autism: the potential for music-based treatments.
|
2010
|
0.87
|
|
37
|
It's all in the family: multiple Toll-like receptors offer promise as novel therapeutic targets for stroke neuroprotection.
|
2009
|
0.86
|
|
38
|
Promoting neurological recovery of function via metaplasticity.
|
2010
|
0.86
|
|
39
|
Understanding the neurobiology of CD200 and the CD200 receptor: a therapeutic target for controlling inflammation in human brains?
|
2013
|
0.85
|
|
40
|
Clinical and molecular aspects of varicella zoster virus infection.
|
2009
|
0.84
|
|
41
|
Recent Progress in Rett Syndrome and MeCP2 Dysfunction: Assessment of Potential Treatment Options.
|
2013
|
0.84
|
|
42
|
Insights into neurogenesis and aging: potential therapy for degenerative disease?
|
2010
|
0.84
|
|
43
|
Association of epilepsy and comorbid conditions.
|
2009
|
0.83
|
|
44
|
The role of intracellular trafficking and the VPS10d receptors in Alzheimer's disease.
|
2012
|
0.83
|
|
45
|
Growth factor regulation of remyelination: behind the growing interest in endogenous cell repair of the CNS.
|
2007
|
0.82
|
|
46
|
Axonal tract tracing for delineating interacting brain regions: implications for Alzheimer's disease-associated memory.
|
2014
|
0.82
|
|
47
|
Aging of the NMDA receptor: from a mouse's point of view.
|
2012
|
0.82
|
|
48
|
ADVANCES IN THE CELL-BASED TREATMENT OF NEONATAL HYPOXIC-ISCHEMIC BRAIN INJURY.
|
2013
|
0.82
|
|
49
|
In vivo astrocytic Ca(2+) signaling in health and brain disorders.
|
2013
|
0.81
|
|
50
|
Fetal neurosurgery: current state of the art.
|
2011
|
0.81
|